These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24592430)

  • 1. Antimicrobial nanotechnology: its potential for the effective management of microbial drug resistance and implications for research needs in microbial nanotoxicology.
    Aruguete DM; Kim B; Hochella MF; Ma Y; Cheng Y; Hoegh A; Liu J; Pruden A
    Environ Sci Process Impacts; 2013 Jan; 15(1):93-102. PubMed ID: 24592430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes.
    Rudramurthy GR; Swamy MK; Sinniah UR; Ghasemzadeh A
    Molecules; 2016 Jun; 21(7):. PubMed ID: 27355939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.
    Mubeen B; Ansar AN; Rasool R; Ullah I; Imam SS; Alshehri S; Ghoneim MM; Alzarea SI; Nadeem MS; Kazmi I
    Antibiotics (Basel); 2021 Nov; 10(12):. PubMed ID: 34943685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles as potential new generation broad spectrum antimicrobial agents.
    Yah CS; Simate GS
    Daru; 2015 Sep; 23():43. PubMed ID: 26329777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of nanotechnology-based nanomaterial as a substitute for antibiotics in monogastric animals.
    Qadeer A; Khan A; Khan NM; Wajid A; Ullah K; Skalickova S; Chilala P; Slama P; Horky P; Alqahtani MS; Alreshidi MA
    Heliyon; 2024 Jun; 10(11):e31728. PubMed ID: 38845989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Paraje MG
    Rev Argent Microbiol; 2023; 55(3):204-205. PubMed ID: 37775252
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial: Microbial nanotechnology: a new frontier in microbiology.
    Verma ML; Joseph PJ; Sen Karaman D
    Front Microbiol; 2023; 14():1296573. PubMed ID: 37928693
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of nanotechnology in combating multi-drug resistant bacteria.
    Singh R; Smitha MS; Singh SP
    J Nanosci Nanotechnol; 2014 Jul; 14(7):4745-56. PubMed ID: 24757944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study.
    Zhang C; Wang Y; Shi G; Han W; Zhao H; Zhang H; Xi X
    BMC Public Health; 2016 Jan; 16():42. PubMed ID: 26775263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of tuberculosis is high in chronic kidney disease patients in South East England and drug resistance common.
    Ostermann M; Palchaudhuri P; Riding A; Begum P; Milburn HJ
    Ren Fail; 2016; 38(2):256-61. PubMed ID: 26726960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
    Grard S; Catho G; Valour F; Bouaziz A; Perpoint T; Braun E; Biron F; Miailhes P; Ferry T; Chidiac C; Souquet PJ; Couraud S; Lina G; Goutelle S; Veziris N; Dumitrescu O; Ader F
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv175. PubMed ID: 26719846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?
    Benbaba S; Isaakidis P; Das M; Jadhav S; Reid T; Furin J
    PLoS One; 2015; 10(12):e0144936. PubMed ID: 26713873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam.
    Hoa NB; Nhung NV; Khanh PH; Hai NV; Quyen BT
    BMC Res Notes; 2015 Dec; 8():809. PubMed ID: 26695761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid profile status of patients treated for multidrug-resistant tuberculosis in state of Meghalaya, India.
    Saharia GK; Ruram AA; Lyngwa J
    Indian J Tuberc; 2015 Jul; 62(3):166-70. PubMed ID: 26600329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled drug treatment for tuberculosis: Past progress and future prospects.
    Hickey AJ; Durham PG; Dharmadhikari A; Nardell EA
    J Control Release; 2016 Oct; 240():127-134. PubMed ID: 26596254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.
    Brigden G; Hewison C; Varaine F
    Infect Drug Resist; 2015; 8():367-78. PubMed ID: 26586956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
    Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
    mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.